Pentixapharm Holding AG Logo

Pentixapharm Holding AG

A clinical-stage company developing first-in-class radiopharmaceuticals.

PTP | F

Overview

Corporate Details

ISIN(s):
DE000A383RV0 (+1 more)
LEI:
3912005VBOVXNDXEQZ36
Country:
Germany
Address:
Robert-Rössle-Straße, 10, 13125 Berlin

Description

Pentixapharm Holding AG is a clinical-stage company focused on developing first-in-class radiopharmaceuticals. The company's research and development centers on CXCR4 ligand-based compounds for diagnostic and therapeutic applications. Its clinical pipeline features two drug candidates that are ready for Phase III trials. One of its lead assets is the radiodiagnostic candidate 68Ga-PentixaFor, which is being prepared for a Phase 3 study for applications in hypertension. The company's core CXCR4 compound has been extensively studied, administered to over 2,000 patients, and is the subject of more than 150 scientific publications.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-03 08:00
Pentixapharm Advances Regulatory Preparations for Phase 3 PANDA Study with Radi…
English 10.2 KB
2025-11-27 10:29
Pentixapharm Holding AG: Eckert Wagniskapital und Fruhphasenfinanzierung GmbH, …
English 6.4 KB
2025-11-12 08:00
Pentixapharm Publishes 9-Month Figures for 2025
English 7.6 KB
2025-11-12 00:00
Q3 statement / Q3 financial report 2025
English 941.4 KB
2025-11-10 08:00
Pentixapharm to Report Third Quarter and First Nine Months 2025 Financial Resul…
English 7.9 KB
2025-11-06 19:55
Pentixapharm Holding AG: Pentixapharm significantly reduces projected loss for …
English 7.1 KB
2025-11-06 10:28
Pentixapharm Holding AG: Eckert Wagniskapital und Fruhphasenfinanzierung GmbH, …
English 6.4 KB
2025-11-03 10:52 English 3.9 KB
2025-10-23 22:12
Pentixapharm Strengthens Pipeline Prioritization and Improves Cost Structure
English 8.6 KB
2025-10-23 20:59
Pentixapharm Holding AG: Pentixapharm Focuses Development on Advanced Clinical …
English 7.5 KB
2025-10-06 11:00
Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New …
English 10.5 KB
2025-09-26 08:00
Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acut…
English 11.3 KB
2025-09-16 15:19
Pentixapharm Holding AG: Eckert Wagniskapital und Fruhphasenfinanzierung GmbH, …
English 6.1 KB
2025-09-15 11:49
Pentixapharm Holding AG: Dr. Andreas Eckert, buy
English 5.8 KB
2025-08-06 00:00
Half-yearly financial report 2025
English 723.4 KB

Automate Your Workflow. Get a real-time feed of all Pentixapharm Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pentixapharm Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pentixapharm Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ALNYLAM PHARMACEUTICALS, INC. Logo
A biopharmaceutical company developing RNA interference (RNAi) therapeutics.
United States of America
ALNY
Alpha Cognition Inc. Logo
A biopharmaceutical company developing treatments for neurodegenerative diseases.
United States of America
ACOG
Alpha Teknova, Inc. Logo
Manufacturer of critical reagents for the life sciences industry.
United States of America
TKNO
ALTERITY THERAPEUTICS LTD Logo
A clinical-stage biotech developing novel treatments for neurodegenerative diseases.
United States of America
ATHE
Altimmune, Inc. Logo
Clinical-stage biopharma developing peptide therapeutics for obesity and liver diseases.
United States of America
ALT
Alto Neuroscience, Inc. Logo
Develops precision medicines for neuropsychiatric conditions using patient biology.
United States of America
ANRO
ALUMIS INC. Logo
Clinical-stage biopharma developing precision medicines for autoimmune diseases.
United States of America
ALMS
Alvotech Holdings S.A Logo
A biotechnology company developing and manufacturing biosimilar medicines worldwide.
Luxembourg
ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage immuno-oncology company developing therapies to combat cancer.
United States of America
ALXO
Alzamend Neuro, Inc. Logo
Develops treatments for neurodegenerative diseases and psychiatric disorders.
United States of America
ALZN

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.